135 related articles for article (PubMed ID: 24749839)
41. Second malignancy in hairy cell leukaemia: no evidence of increased incidence after treatment with interferon alpha.
Pawson R; A'Hern R; Catovsky D
Leuk Lymphoma; 1996 Jun; 22(1-2):103-6. PubMed ID: 8724535
[TBL] [Abstract][Full Text] [Related]
42. Pentostatin treatment for hairy cell leukemia patients who failed initial therapy with recombinant alpha-interferon: a report of CALGB study 8515.
Golomb HM; Dodge R; Mick R; Budman D; Hutchison R; Horning SJ; Schiffer CA
Leukemia; 1994 Dec; 8(12):2037-40. PubMed ID: 7807991
[TBL] [Abstract][Full Text] [Related]
43. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
[TBL] [Abstract][Full Text] [Related]
44. Long-term follow-up of interferon-alpha induction and low-dose maintenance therapy in hairy cell leukemia.
Benz R; Siciliano RD; Stussi G; Fehr J
Eur J Haematol; 2009 Mar; 82(3):194-200. PubMed ID: 19077050
[TBL] [Abstract][Full Text] [Related]
45. [Treatment of hairy cell leukemia with cladribine].
Aurer I; Mitrović Z; Kovacević-Metelko J; Radman I; Basić-Kinda S; Gjadrov-Kuvezdić K; Jakić-Razumović J; Dubravcić K; Ries S; Nola M; Zupancic-Salek S; Labar B
Lijec Vjesn; 2007; 129(3-4):80-3. PubMed ID: 17557550
[TBL] [Abstract][Full Text] [Related]
46. [Analysis of clinical and laboratory characteristics and survival with hairy cell leukemia].
Zhang YR; Wang YY; Li ZJ; Yi SH; Feng XY; Liu W; Qi JY; Zou DH; Zhao YZ; Qiu LG
Zhonghua Yi Xue Za Zhi; 2012 Dec; 92(46):3250-3. PubMed ID: 23328507
[TBL] [Abstract][Full Text] [Related]
47. Is it really possible to cure hairy cell leukemia patients only with frontline therapy?
Zinzani PL; Stefoni V; Broccoli A; Pellegrini C; Gandolfi L; Casadei B; Maglie R; Pileri S; Argnani L
Ann Hematol; 2014 Sep; 93(9):1565-9. PubMed ID: 24752417
[TBL] [Abstract][Full Text] [Related]
48. Which role for rituximab in hairy cell leukemia? Reflections on six cases.
Malfuson JV; Fagot T; Konopacki J; Souleau B; Cremades S; de Revel T
Acta Haematol; 2010; 123(2):110-6. PubMed ID: 20051682
[TBL] [Abstract][Full Text] [Related]
49. Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia.
Zheng G; Chattopadhyay S; Sud A; Sundquist K; Sundquist J; Försti A; Houlston R; Hemminki A; Hemminki K
Br J Haematol; 2019 Apr; 185(2):232-239. PubMed ID: 30706458
[TBL] [Abstract][Full Text] [Related]
50. Current Therapy and New Directions in the Treatment of Hairy Cell Leukemia: A Review.
Sarvaria A; Topp Z; Saven A
JAMA Oncol; 2016 Jan; 2(1):123-9. PubMed ID: 26513168
[TBL] [Abstract][Full Text] [Related]
51. Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Italian Cooperative Group for Hairy Cell Leukemia.
Frassoldati A; Lamparelli T; Federico M; Annino L; Capnist G; Pagnucco G; Dini E; Resegotti L; Damasio EE; Silingardi V
Leuk Lymphoma; 1994 Apr; 13(3-4):307-16. PubMed ID: 7519510
[TBL] [Abstract][Full Text] [Related]
52. Observations on the development of T-cell leukaemia in the patient successfully treated by interferon-alpha for typical hairy cell leukaemia (HCL).
Demeter J; Paloczi K
Leukemia; 1992 Nov; 6(11):1235-6. PubMed ID: 1290544
[No Abstract] [Full Text] [Related]
53. Synchronous gastric and ampullary adenocarcinomas in a hairy cell leukemia patient treated with pentostatin eight years prior.
Senatore FJ; Dasanu CA
J Oncol Pharm Pract; 2016 Jun; 22(3):543-7. PubMed ID: 25712625
[TBL] [Abstract][Full Text] [Related]
54. Incidence and significance of abdominal lymphadenopathy in hairy cell leukaemia.
Mercieca J; Puga M; Matutes E; Moskovic E; Salim S; Catovsky D
Leuk Lymphoma; 1994; 14 Suppl 1():79-83. PubMed ID: 7820058
[TBL] [Abstract][Full Text] [Related]
55. Targeted therapy for treatment of patients with classical hairy cell leukemia.
Moore JE; Delibert K; Baran AM; Evans AG; Liesveld JL; Zent CS
Leuk Res; 2021 Mar; 102():106522. PubMed ID: 33582427
[TBL] [Abstract][Full Text] [Related]
56. Patients with relapsed/refractory hairy-cell leukemia.
Paillassa J; Troussard X
Cancer Rep (Hoboken); 2022 Mar; 5(3):e1495. PubMed ID: 34250762
[TBL] [Abstract][Full Text] [Related]
57. Hairy cell leukemia in Hong Kong Chinese: a 12-year retrospective survey.
Au WY; Kwong YL; Ma SK; Mak YK; Wong KF; Lei KI; Ng MH; Chan JC; Lin SY; Lee KK; Liang R
Hematol Oncol; 2000 Dec; 18(4):155-159. PubMed ID: 11135356
[TBL] [Abstract][Full Text] [Related]
58. Increased incidence of second neoplasms in patients treated with interferon alpha 2b for hairy cell leukemia: a clinicopathologic assessment.
Kampmeier P; Spielberger R; Dickstein J; Mick R; Golomb H; Vardiman JW
Blood; 1994 May; 83(10):2931-8. PubMed ID: 8180388
[TBL] [Abstract][Full Text] [Related]
59. Hairy cell leukaemia: descriptive epidemiology and a case-control study.
Staines A; Cartwright RA
Br J Haematol; 1993 Dec; 85(4):714-7. PubMed ID: 7918034
[TBL] [Abstract][Full Text] [Related]
60. Hairy cell leukemia: clinical presentation and follow-up of 211 patients.
Flandrin G; Sigaux F; Sebahoun G; Bouffette P
Semin Oncol; 1984 Dec; 11(4 Suppl 2):458-71. PubMed ID: 6505708
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
